Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44


The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans.

Biolo G, Secchiero P, De Giorgi S, Tisato V, Zauli G.

Clin Nutr. 2012 Dec;31(6):1018-21. doi: 10.1016/j.clnu.2012.04.016. Epub 2012 May 24.


Downregulation of FLIP by cycloheximide sensitizes human fat cells to CD95-induced apoptosis.

Fischer-Posovszky P, Keuper M, Nagel S, Hesse D, Schürmann A, Debatin KM, Strauss G, Wabitsch M.

Exp Cell Res. 2011 Sep 10;317(15):2200-9. doi: 10.1016/j.yexcr.2011.06.016. Epub 2011 Jul 2.


TNFR1-induced activation of the classical NF-κB pathway.

Wajant H, Scheurich P.

FEBS J. 2011 Apr;278(6):862-76. doi: 10.1111/j.1742-4658.2011.08015.x. Epub 2011 Feb 8. Review.


The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity.

Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Müller M, van den Berg WB, van Rooijen N, Wabitsch M, Kullberg BJ, van der Meer JW, Kanneganti T, Tack CJ, Netea MG.

Cell Metab. 2010 Dec 1;12(6):593-605. doi: 10.1016/j.cmet.2010.11.011.


The nuclear hormone receptor PPARγ as a therapeutic target in major diseases.

Schmidt MV, Brüne B, von Knethen A.

ScientificWorldJournal. 2010 Nov 4;10:2181-97. doi: 10.1100/tsw.2010.213. Review.


Fas activation in adipocytes impairs insulin-stimulated glucose uptake by reducing Akt.

Wueest S, Rapold RA, Schoenle EJ, Konrad D.

FEBS Lett. 2010 Oct 8;584(19):4187-92. doi: 10.1016/j.febslet.2010.08.052. Epub 2010 Sep 7.


TRAIL: a sword for killing tumors.

Wang S.

Curr Med Chem. 2010;17(29):3309-17. Review.


New insights into apoptosis signaling by Apo2L/TRAIL.

Gonzalvez F, Ashkenazi A.

Oncogene. 2010 Aug 26;29(34):4752-65. doi: 10.1038/onc.2010.221. Epub 2010 Jun 7. Review.


Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS.

J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10.


Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis.

Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, Fulda S.

FASEB J. 2010 Jun;24(6):1997-2009. doi: 10.1096/fj.09-142943. Epub 2010 Jan 22.


Human SGBS cells - a unique tool for studies of human fat cell biology.

Fischer-Posovszky P, Newell FS, Wabitsch M, Tornqvist HE.

Obes Facts. 2008;1(4):184-9. doi: 10.1159/000145784. Epub 2008 Aug 14. Review.


Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice.

Wueest S, Rapold RA, Schumann DM, Rytka JM, Schildknecht A, Nov O, Chervonsky AV, Rudich A, Schoenle EJ, Donath MY, Konrad D.

J Clin Invest. 2010 Jan;120(1):191-202. doi: 10.1172/JCI38388. Epub 2009 Dec 1.


Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW.

Ann Oncol. 2010 Feb;21(2):376-81. doi: 10.1093/annonc/mdp292. Epub 2009 Jul 24.


c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists.

Fernández-Veledo S, Vila-Bedmar R, Nieto-Vazquez I, Lorenzo M.

J Clin Endocrinol Metab. 2009 Sep;94(9):3583-93. doi: 10.1210/jc.2009-0558. Epub 2009 Jun 30.


Following TRAIL's path in the immune system.

Falschlehner C, Schaefer U, Walczak H.

Immunology. 2009 Jun;127(2):145-54. doi: 10.1111/j.1365-2567.2009.03058.x. Review.


Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes.

Guilherme A, Tesz GJ, Guntur KV, Czech MP.

J Biol Chem. 2009 Jun 19;284(25):17082-91. doi: 10.1074/jbc.M809042200. Epub 2009 Mar 25.


Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

Ashkenazi A, Holland P, Eckhardt SG.

J Clin Oncol. 2008 Jul 20;26(21):3621-30. doi: 10.1200/JCO.2007.15.7198. Review.


Caspase-mediated degradation of PPARgamma proteins in adipocytes.

He F, Doucet JA, Stephens JM.

Obesity (Silver Spring). 2008 Aug;16(8):1735-41. doi: 10.1038/oby.2008.269. Epub 2008 May 22.


Trail receptors: targets for cancer therapy.

Humphreys RC, Halpern W.

Adv Exp Med Biol. 2008;615:127-58. doi: 10.1007/978-1-4020-6554-5_7. Review.


A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility.

Keller MP, Choi Y, Wang P, Davis DB, Rabaglia ME, Oler AT, Stapleton DS, Argmann C, Schueler KL, Edwards S, Steinberg HA, Chaibub Neto E, Kleinhanz R, Turner S, Hellerstein MK, Schadt EE, Yandell BS, Kendziorski C, Attie AD.

Genome Res. 2008 May;18(5):706-16. doi: 10.1101/gr.074914.107. Epub 2008 Mar 17.

Items per page

Supplemental Content

Write to the Help Desk